Capstone Investment Advisors LLC Makes New Investment in LifeStance Health Group, Inc. $LFST

Capstone Investment Advisors LLC acquired a new stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 51,686 shares of the company’s stock, valued at approximately $554,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in LFST. Royal Bank of Canada boosted its position in shares of LifeStance Health Group by 63.4% in the 1st quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock valued at $468,000 after purchasing an additional 27,244 shares during the period. AQR Capital Management LLC raised its holdings in LifeStance Health Group by 223.0% during the 1st quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock worth $343,000 after buying an additional 35,554 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in LifeStance Health Group by 3.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock worth $952,000 after buying an additional 4,169 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in LifeStance Health Group by 1.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock valued at $4,100,000 after buying an additional 11,331 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in LifeStance Health Group by 10.2% during the second quarter. JPMorgan Chase & Co. now owns 550,657 shares of the company’s stock valued at $2,847,000 after buying an additional 51,154 shares in the last quarter. 85.50% of the stock is currently owned by institutional investors.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, CTO Vukasin Paunovich sold 44,394 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $10.85, for a total value of $481,674.90. Following the completion of the sale, the chief technology officer directly owned 247,446 shares of the company’s stock, valued at $2,684,789.10. This represents a 15.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Lisa K. Miller sold 47,912 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $519,845.20. Following the completion of the sale, the chief operating officer owned 281,289 shares in the company, valued at $3,051,985.65. This represents a 14.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 14,629,850 shares of company stock worth $154,952,012. Insiders own 3.50% of the company’s stock.

LifeStance Health Group Stock Up 0.1%

Shares of LFST stock opened at $12.31 on Friday. The stock’s 50 day simple moving average is $11.19 and its 200 day simple moving average is $8.60. LifeStance Health Group, Inc. has a twelve month low of $4.77 and a twelve month high of $12.97. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38. The company has a market capitalization of $4.77 billion, a price-to-earnings ratio of 94.70 and a beta of 1.14.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. The company had revenue of $435.35 million for the quarter, compared to the consensus estimate of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The firm’s revenue was up 26.1% compared to the same quarter last year. During the same period last year, the business posted ($0.01) earnings per share. As a group, research analysts predict that LifeStance Health Group, Inc. will post 0.16 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on LFST shares. Canaccord Genuity Group boosted their price target on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Barclays lifted their price objective on shares of LifeStance Health Group from $9.00 to $13.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 14th. Zacks Research lowered LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Weiss Ratings raised LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. upped their price target on LifeStance Health Group from $9.00 to $13.00 and gave the company a “neutral” rating in a research report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, LifeStance Health Group presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.38.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.